Comparative Pharmacology
Head-to-head clinical analysis: EUTHROID 1 versus EUTHROID 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTHROID 1 versus EUTHROID 3.
EUTHROID-1 vs EUTHROID-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
None Documented
None Documented
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Category C
Category C
Thyroid Hormone Replacement
Thyroid Hormone Replacement